Sangamo Therapeutics France is the French subsidiary of Sangamo Therapeutics Inc. Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and gene regulation. For more information about Sangamo, visit www.sangamo.com. Sangamo Therapeutics France was formerly TxCell and was acquired by Sangamo Q4 2018.